The manufacturing of medicinal products is for us not only a matter of implementing a certain technological process, but a human mission based on high standards of quality, safety and efficacy of medications
SOPHARMA AD hereby informs that from 14 January 2016 up to and including 20 January 2016 the Company bought 2000 own shares representing 0.0015% of the share capital of the Company, at a total value of 5 312.00 BGN on the Bulgarian Stock Exchange, the average price per share was 2.66 BGN. The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010. The total number of treasury shares after these transactions is 5 221 296, representing 3.87% of the share capital of the Company.
Sopharma AD notifies that on 21 January 2016 Sopharma AD deposited with the Finacnial Supervision Commission an agreement for termination of the Contract for transformation through merger in accordance with the requirements of art. 262d and following of the Commercial Act (CA) between Sopharma AD, Sofia, UIC 831902088, hereinafter referred to as "receiving company" and Momina Krepost AD, Veliko Tarnovo, Str. Magistralna 23, UIC 104055543, hereinafter referred to as "transferring company".
Sopharma AD notifies that for January 2016 the Company recorded an increase of sales revenues of 40% compared to the same month of 2015, including 2% increase in domestic sales and 99% increase in export sales. The increase in export sales is due to the low baseline from 2015, when due to the volatility of the Russian ruble the sales on the Russian market were temporarily stopped.
Sopharma AD notifies that for February 2016 the Company recorded a decrease of sales revenues of 2% compared to the same month of 2015, including 7% increase of domestic sales and 7% decrease of export sales. For the first two months of this year, revenues from sales increased by 17% compared to the same period of 2015, including 4% increase of domestic sales and a 28% increase of export sales.
Sopharma AD (the “Company”) notifies that on 30 September 2015 Sopharma AD, Sofia, UIC 831902088, hereinafter referred to as "receiving company" and Momina Krepost AD, Veliko Tarnovo, Str. Magistralna 23, UIC 104055543, hereinafter referred to as "transferring company" signed a Contract for transformation through merger in accordance with the requirements of art. 262d and following of the Commercial Act (CA), as a result of which all assets of Momina Krepost AD shall be transferred to Sopharma AD and the latter shall become its legal successor.
Sopharma AD notifies that for March 2016 the Company recorded a decrease of sales revenues of 19% compared to the same month of 2015, including 17% increase of domestic sales and 36% decrease of export sales. For the first three months of this year, revenues from sales increased by 2% compared to the same period of 2015, including 8% increase of domestic sales and a 1% decrease of export sales.
Sopharma AD (the “Company”) announces that on 22 October 2015 the Company bought 3 080 000 shares from the capital of Medika AD. After this transaction, the share of Sopharma AD in the capital of Medika AD increased to 66.72%.
Sopharma AD notifies that for October 2015 the Company recorded same level of sales revenues compared to the same month of 2014, including 2% increase of domestic sales and 2% decrease of export sales.
For the first ten months of this year, revenues from sales decreased by 16% compared to the same period of 2014, including 2% increase of domestic sales and a 25% decrease of export sales.
Sopharma AD notifies that for November 2015 the Company recorded a decrease of sales revenues of 5% compared to the same month of 2014, including 3% increase of domestic sales and 9% decrease of export sales.
For the first eleven months of this year, revenues from sales decreased by 15% compared to the same period of 2014, including 2% increase of domestic sales and a 23% decrease of export sales.
